1. Pink Sheet
  2. >>Advanced Technologies
  3. >>AI

AI In Drug Development: FDA Wants To Know How To Assure Data Integrity, Transparency, Reliability

 
• By Brenda Sandburg

US FDA asks stakeholders how they are addressing bias, reproducibility and data privacy in application of AI/ML. Discussion paper describes current and potential uses of artificial intelligence and machine learning in drug development.

Artificial intelligence
FDA issues discussion paper on use of artificial intelligence and machine learning in drug devleopment • Source: Shutterstock

The US Food and Drug Administration laid out the challenges that need to be addressed in using artificial intelligence and machine learning in drug development, from transparency to the quality, reliability and representativeness of data and monitoring and validation of AL/ML models.

In a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

More from Advanced Technologies

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 
• By Eliza Slawther

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By Kate Rawson

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.